Anti-TNF-α antibody treatments, such as infliximab or adalimumab, have been found to attenuate aberrant macrophage activation by significantly reducing CD163 expression on circulating CD14+ monocytes, and normalised circulating sCD163 levels, in patients with ulcerative colitis [76]. This evidence concerns the gene CD163 and ulcerative colitis.